Journal ArticleDOI
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Bernard Escudier,Robert J. Motzer,Padmanee Sharma,John Wagstaff,Elizabeth R. Plimack,Hans J. Hammers,Frede Donskov,Howard Gurney,Jeffrey A. Sosman,Pawel Zalewski,Ulrika Harmenberg,David F. McDermott,Toni K. Choueiri,Martin Eduardo Richardet,Yoshihiko Tomita,Alain Ravaud,Justin Doan,Huanyu Zhao,Helene Hardy,Saby George +19 more
Reads0
Chats0
TLDR
A subset of patients with advanced renal cell carcinoma and disease progression may continue to benefit from nivolumab treatment beyond progression as evidenced by tumor reduction postprogression and an acceptable safety profile.About:
This article is published in European Urology.The article was published on 2017-09-01. It has received 187 citations till now. The article focuses on the topics: Nivolumab & Response Evaluation Criteria in Solid Tumors.read more
Citations
More filters
Journal ArticleDOI
Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Sang Eun Won,Hyojung Park,Sangil Byun,Junhee Pyo,J.H. Kim,Chang-Min Choi,Jae Cheol Lee,Dae Ho Lee,Sang-We Kim,Shinkyo Yoon,Kyung Won Kim +10 more
TL;DR: Based on iRECIST scheme, PsP and TBP may be associated with survival benefit in NSCLC patients treated with ICI and treatment beyond RECIST1.1-defined progressive disease.
Journal ArticleDOI
Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.
Lukas Jennewein,Georg Bartsch,Kilian M. Gust,Hans Michael Kvasnicka,Axel Haferkamp,Roman A. Blaheta,Michel Mittelbronn,Patrick N. Harter,Jens Mani +8 more
TL;DR: Tissue micro array based analysis of 84 patients with testicular cancer demonstrated that PD-L1 was significantly upregulated in testicular tumors and PD-1 positive cells significantly infiltrated the testicular tumor when compared with normal testicular tissue, and suggested that the anti-PD-1/PD-L 1 immunotherapy and theAnti-angiogenic therapy, sequentially or in combination, may be a promising option in the treatment of testicular cancers.
Journal ArticleDOI
Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
TL;DR: It is suggested that a poor PS is significantly associated with poor prognosis in mRCC patients receiving TKIs.
Journal ArticleDOI
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
Xiangwei Ge,Zhibo Zhang,Sujie Zhang,Fang Yuan,Fan Zhang,Xiang Yan,Xiao Han,Junxun Ma,Lijie Wang,Haitao Tao,Xiaoyan Li,Xiaoyu Zhi,Zhiyue Huang,Paul Hofman,Arsela Prelaj,Giuseppe Luigi Banna,Luciano Mutti,Yi Hu,Jinliang Wang +18 more
TL;DR: Wang et al. as mentioned in this paper investigated the efficacy of immunotherapy beyond progression (IBP) in patients with advanced non-small cell lung cancer (aNSCLC) under real-world conditions.
Journal ArticleDOI
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Izabela Łasińska,Tomasz Kolenda,Anna Teresiak,Katarzyna Lamperska,Łukasz Galus,Jacek Mackiewicz +5 more
TL;DR: Very encouraging results have been shown in early phase studies evaluating the combination of immune-checkpoint inhibitors with tumor microenvironment immunosuppressive inhibitors, but further research in the field of biomarkers for effective immunotherapy is needed, as the treatment is still ineffective in most patients.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal Article
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
Hirokazu Watanabe,Morihito Okada,Yasushi Kaji,Miyako Satouchi,Yozo Sato,Yuichiro Yamabe,Hiroaki Onaya,Masahiro Endo,Miyuki Sone,Yasuaki Arai +9 more
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal ArticleDOI
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok,Axel Hoos,Steven J. O'Day,Jeffrey S. Weber,Omid Hamid,Céleste Lebbé,Michele Maio,Michael Binder,Oliver Bohnsack,Geoffrey M. Nichol,R. Humphrey,F. Stephen Hodi +11 more
TL;DR: Systematic criteria, designated immune-related response criteria, were defined in an attempt to capture additional response patterns observed with immune therapy in advanced melanoma beyond those described by Response Evaluation Criteria in Solid Tumors or WHO criteria.
Summary of product characteristics
Helen Andrew,Gemma Gossedge,Julie Croft,Neil Corrigan,Julia Brown,Nicholas West,Philip Quirke,Damian Tolan,Ronan A. Cahill,David Jayne +9 more
TL;DR: Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
Related Papers (5)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more